These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27250825)

  • 101. Relaxin suppresses atrial fibrillation, reverses fibrosis and reduces inflammation in aged hearts.
    Romero G; Martin B; Gabris B; Salama G
    Biochem Pharmacol; 2024 Jul; 227():116407. PubMed ID: 38969298
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.
    Zeisberg M; Kalluri R
    Am J Physiol Cell Physiol; 2013 Feb; 304(3):C216-25. PubMed ID: 23255577
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Chronic liver diseases: From development to novel pharmacological therapies: IUPHAR Review 37.
    Borrello MT; Mann D
    Br J Pharmacol; 2023 Nov; 180(22):2880-2897. PubMed ID: 35393658
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Cytokine mediated tissue fibrosis.
    Borthwick LA; Wynn TA; Fisher AJ
    Biochim Biophys Acta; 2013 Jul; 1832(7):1049-60. PubMed ID: 23046809
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Chronic intermittent hypoxia accelerates coronary microcirculatory dysfunction in insulin-resistant Goto-Kakizaki rats.
    Chen YC; Inagaki T; Fujii Y; Schwenke DO; Tsuchimochi H; Edgley AJ; Umetani K; Zhang Y; Kelly DJ; Yoshimoto M; Nagai H; Evans RG; Kuwahira I; Shirai M; Pearson JT
    Am J Physiol Regul Integr Comp Physiol; 2016 Aug; 311(2):R426-39. PubMed ID: 27252472
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Serelaxin as a novel therapeutic opposing fibrosis and contraction in lung diseases.
    Lam M; Royce SG; Samuel CS; Bourke JE
    Pharmacol Ther; 2018 Jul; 187():61-70. PubMed ID: 29447958
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Vascular actions of relaxin: nitric oxide and beyond.
    Leo CH; Jelinic M; Ng HH; Marshall SA; Novak J; Tare M; Conrad KP; Parry LJ
    Br J Pharmacol; 2017 May; 174(10):1002-1014. PubMed ID: 27590257
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Novel Anti-fibrotic Therapies.
    McVicker BL; Bennett RG
    Front Pharmacol; 2017; 8():318. PubMed ID: 28620300
    [TBL] [Abstract][Full Text] [Related]  

  • 109. ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.
    Kocan M; Sarwar M; Ang SY; Xiao J; Marugan JJ; Hossain MA; Wang C; Hutchinson DS; Samuel CS; Agoulnik AI; Bathgate RAD; Summers RJ
    Sci Rep; 2017 Jun; 7(1):2968. PubMed ID: 28592882
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Understanding relaxin signalling at the cellular level.
    Valkovic AL; Bathgate RA; Samuel CS; Kocan M
    Mol Cell Endocrinol; 2019 May; 487():24-33. PubMed ID: 30592984
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways.
    Ng HH; Shen M; Samuel CS; Schlossmann J; Bennett RG
    Mol Cell Endocrinol; 2019 May; 487():59-65. PubMed ID: 30660699
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy.
    Hu M; Wang Y; Xu L; An S; Tang Y; Zhou X; Li J; Liu R; Huang L
    Nat Commun; 2019 Jul; 10(1):2993. PubMed ID: 31278269
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Peptide hormone relaxin: from bench to bedside.
    Jelinic M; Marshall SA; Stewart D; Unemori E; Parry LJ; Leo CH
    Am J Physiol Regul Integr Comp Physiol; 2018 Jun; 314(6):R753-R760. PubMed ID: 29412692
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis.
    Kaftanovskaya EM; Ng HH; Soula M; Rivas B; Myhr C; Ho BA; Cervantes BA; Shupe TD; Devarasetty M; Hu X; Xu X; Patnaik S; Wilson KJ; Barnaeva E; Ferrer M; Southall NT; Marugan JJ; Bishop CE; Agoulnik IU; Agoulnik AI
    FASEB J; 2019 Nov; 33(11):12435-12446. PubMed ID: 31419161
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Liver fibrosis.
    Aydın MM; Akçalı KC
    Turk J Gastroenterol; 2018 Jan; 29(1):14-21. PubMed ID: 29391303
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Relaxin and fibrosis: Emerging targets, challenges, and future directions.
    Kanai AJ; Konieczko EM; Bennett RG; Samuel CS; Royce SG
    Mol Cell Endocrinol; 2019 May; 487():66-74. PubMed ID: 30772373
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Targeting the Relaxin Pathway for Liver Disease Treatment.
    Bennett RG
    Eur Med J Hepatol; 2018 May; 6(1):80-87. PubMed ID: 31360529
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease.
    Lee KC; Hsieh YC; Chan CC; Sun HJ; Huang YH; Hou MC; Lin HC
    Lab Invest; 2019 Jul; 99(8):1203-1216. PubMed ID: 30918325
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Relaxin gene therapy: A promising new treatment option for various diseases with aberrant fibrosis or irregular angiogenesis.
    Hong J; Yun CO
    Mol Cell Endocrinol; 2019 May; 487():80-84. PubMed ID: 30641100
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Nanoparticles for the treatment of liver fibrosis.
    Poilil Surendran S; George Thomas R; Moon MJ; Jeong YY
    Int J Nanomedicine; 2017; 12():6997-7006. PubMed ID: 29033567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.